• Loading metrics

Efficacy and Safety of Praziquantel in Preschool-Aged Children in an Area Co-Endemic for Schistosoma mansoni and S. haematobium

  • Jean T. Coulibaly,

    Affiliations Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland, University of Basel, Basel, Switzerland, Unité de Formation et de Recherche Biosciences, Université Félix Houphouët-Boigny, Abidjan, Côte d'Ivoire, Centre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire

  • Yve K. N'Gbesso,

    Affiliation Centre de Santé Rural d'Azaguié, Departement d'Agboville, Azaguié, Côte d'Ivoire

  • Stefanie Knopp,

    Affiliations Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland, University of Basel, Basel, Switzerland

  • Jennifer Keiser,

    Affiliations University of Basel, Basel, Switzerland, Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland

  • Eliézer K. N'Goran,

    Affiliations Unité de Formation et de Recherche Biosciences, Université Félix Houphouët-Boigny, Abidjan, Côte d'Ivoire, Centre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, Côte d'Ivoire

  • Jürg Utzinger

    Affiliations Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland, University of Basel, Basel, Switzerland

Efficacy and Safety of Praziquantel in Preschool-Aged Children in an Area Co-Endemic for Schistosoma mansoni and S. haematobium

  • Jean T. Coulibaly, 
  • Yve K. N'Gbesso, 
  • Stefanie Knopp, 
  • Jennifer Keiser, 
  • Eliézer K. N'Goran, 
  • Jürg Utzinger



In sub-Saharan Africa the recommended strategy to control schistosomiasis is preventive chemotherapy. Emphasis is placed on school-aged children, but in high endemicity areas, preschool-aged children are also at risk, and hence might need treatment with praziquantel. Since a pediatric formulation (e.g., syrup) is not available outside of Egypt, crushed praziquantel tablets are used, but the efficacy and safety of this treatment regimen is insufficiently studied.


We assessed the efficacy and safety of crushed praziquantel tablets among preschool-aged children (<6 years) in the Azaguié district, south Côte d'Ivoire, where Schistosoma mansoni and S. haematobium coexist. Using a cross-sectional design, children provided two stool and two urine samples before and 3 weeks after treatment. Crushed praziquantel tablets, mixed with water, were administered at a dose of 40 mg/kg. Adverse events were assessed and graded 4 and 24 hours posttreatment by interviewing mothers/guardians.

Principal Findings

Overall, 160 preschool-aged children had at least one stool and one urine sample examined with duplicate Kato-Katz thick smears and a point-of-care circulating cathodic antigen (POC-CCA) cassette for S. mansoni, and urine filtration for S. haematobium diagnosis before and 3 weeks after praziquantel administration. According to the Kato-Katz and urine filtration results, we found high efficacy against S. mansoni (cure rate (CR), 88.6%; egg reduction rate (ERR), 96.7%) and S. haematobium (CR, 88.9%; ERR, 98.0%). POC-CCA revealed considerably lower efficacy against S. mansoni (CR, 53.8%). Treatment was generally well tolerated, but moderately severe adverse events (i.e., body and face inflammation), were observed in four Schistosoma egg-negative children.


Crushed praziquantel administered to preschool-aged children at a dose of 40 mg/kg is efficacious against S. mansoni and S. haematobium in a co-endemic setting of Côte d'Ivoire. Further research is required with highly sensitive diagnostic tools and safety must be investigated in more depth.

Trial Registration ISRCTN53172722

Author Summary

Schistosomiasis is a parasitic worm infection that plagues more than 200 million people in the developing world, particularly in sub-Saharan Africa. The current strategy to control schistosomiasis is to regularly administer the deworming drug praziquantel to school-aged children. Younger children before reaching school-age are not included in these deworming campaigns, because they are considered at low risk of schistosomiasis, and because the amount of available data to evaluate the safety of praziquantel in young children is insufficient. We conducted a study in two villages in southern Côte d'Ivoire and examined the stool and urine of more than 250 children (<6 years) for schistosome eggs and antigens. Children were treated with crushed praziquantel tablets (40 mg/kg) and the efficacy of this treatment was determined 3 weeks after treatment. The safety of the treatment was assessed by interviewing mothers of treated children for adverse events (e.g., abdominal pain, diarrhea, and headache). Complete data records were available for 160 children. Praziquantel cleared most of the infections. The treatment was generally well tolerated, but we observed four children who were not infected at the baseline survey who developed face and body inflammation that required close supervision by the study physician.


Schistosomiasis is still a major public health problem in many parts of the developing world, especially in sub-Saharan Africa [1][5]. Indeed, more than 200 million people are infected, with about half of them suffering from morbid sequelae, including hematuria, dysuria, nutritional deficiencies, anemia, and delayed physical and cognitive development [1], [5][9]. The anthelmintic drug praziquantel is the cornerstone for morbidity control with millions of people treated every year [10][14]. Morbidity control is emphasized since the mid-1980s, and this strategy has been reinforced in 2001 by the World Health Assembly (WHA) resolution 54.19, which urged member states to regularly de-worm at least 75% and up to 100% of school-aged children at risk of schistosomiasis and soil-transmitted helminthiasis [10], [15].

Preschool-aged children (individuals below the age of 5–6 years) are currently excluded from preventive chemotherapy control campaigns. The main reasons for this exclusion are that preschool-aged children are believed to be at low risk of schistosomiasis [16], and that there is insufficient data documenting the safety and efficacy of praziquantel in this age group [17], [18]. However, recent studies carried out in different parts of East and West Africa showed that in high endemicity areas a considerable proportion of preschool-aged children are already infected with Schistosoma, and hence treatment might need to be extended to younger age groups in such high-risk areas [19][29].

With regard to morbidity control of schistosomiasis using praziquantel, it is important to note that an appropriate pediatric formulation for treating preschool-aged children is currently not available outside of Egypt (i.e., praziquantel syrup, Epiquantel, manufactured by the Egyptian International Pharmaceutical Industries Co. A.R.E., Cairo, Egypt). Hence, a common approach in high endemicity areas is to use praziquantel tablets (600 mg), crush them between two spoons, mix with water or fruit juice, and then administer orally to preschool-aged children at a dose of 40 mg/kg [17], [23], [24]. Recent studies using Epiquantel in preschool-aged children revealed similar efficacy than crushed praziquantel tablets [28], [30].

The study reported here was designed to assess the efficacy and safety of crushed praziquantel tablets in preschool-aged children (<6 years) in an area where Schistosoma mansoni and S. haematobium coexist [31], [32]. Our findings, along with other investigations pertaining to the epidemiology of schistosomiasis in preschool-aged children, may be useful to further optimize the control of schistosomiasis in a currently neglected age group.


Ethics Statement

Ethical approval was granted by the Ministry of Health and Public Hygiene of Côte d'Ivoire (reference no. 4248/2010/MSHP/CNER). The trial is registered with (identifier: ISRCTN 53172722) and the protocol is available as Supporting Information (Protocol S1). Local authorities of the Azaguié district were informed about the purpose, procedures, and potential risks and benefits of the study. In the absence of recent census data, an exhaustive door-to-door survey was carried out to identify all preschool-aged children (<6 years) in the two selected villages. Parents or guardians of eligible children were informed about the objectives of the study and asked to provide written informed consent on behalf of their children. Only those preschool-aged children who had written informed consent from their parents/guardians were included.

Participation was voluntary and parents/guardians could withdraw their child from the study anytime without further obligation. At the end of the study, anthelmintic drugs (i.e., praziquantel against schistosomiasis and albendazole against soil-transmitted helminthiasis) were offered free of charge to all community members.

Study Area and Population

The study was conducted between June and November 2011 in two villages located in the district of Azaguié, southern Côte d'Ivoire: Azaguié Makouguié (geographical co-ordinates 05°37′33″N latitude, 04°09′04″W longitude) and Azaguié M'Bromé (05°39′42″N, 04°08′38″W). Recent studies have shown that S. mansoni and S. haematobium are co-endemic in Azaguié [31][33]. Villagers are mainly engaged in subsistence farming. Both villages lack access to clean water and improved sanitation.

Study Design and Sample Size

We pursued an intervention study (i.e., praziquantel administration), including children of both sexes below the age of 6 years. Children's infection with S. mansoni and S. haematobium was assessed during a baseline cross-sectional survey and again 3 weeks posttreatment using standardized, quality-controlled methods. The STROBE checklist is available as Supporting Information (Checklist S1).

With the overarching goal to further the understanding of the epidemiology, diagnosis, and control of schistosomiasis in preschool-aged children, we aimed at a sample of about 200 individuals, as recommended by statistical textbooks in health studies [34]. Our population census carried out in June 2011 revealed 367 preschool-age children. We assumed that the prevalence of S. mansoni in preschool-aged children would be around 20% (i.e., a quarter of the 80% S. mansoni infection prevalence observed in school-aged children in Azaguié in 2010 [31]) and that about 70% of the preschool-aged children would comply (lower rate than among school-aged children due to the difficulty to obtain biological samples in this younger age group). Aiming for a precision of 5%, we finally decided to include all 367 registered preschool-aged children.

Inclusion Criteria

We adhered to the following inclusion criteria: (i) preschool-aged children (<6 years); (ii) written informed consent by parents/guardians; (iii) submission of at least one sufficiently large stool sample for duplicate Kato-Katz thick smears, and one urine sample for a 10 ml filtrate and a single point-of-care circulating cathodic antigen (POC-CCA) cassette test; (iv) no abnormal medical condition, as judged by the study physician on the day of the treatment; (v) no recent anthelmintic treatment (within the past 4 weeks) according to a parental questionnaire; and (vi) no participation in any other clinical trial.

Parasitological and Clinical Examinations

The door-to-door census carried out in June 2011 to establish up-to-date census data generated lists of preschool-aged children, including their name, age, sex, and geographical coordinates of the household. Mothers/guardians of the preschool-aged children were provided with plastic containers labeled with unique identifiers (IDs) and they were asked to obtain a fresh stool and urine sample of their child. Stool and urine samples were collected at any time of the day due to the difficulty of collecting biological samples in this age group. Our aim was to obtain two stool and two urine samples over two consecutive days from each participating child.

Laboratory Procedures

Stool and urine samples were transferred to a nearby laboratory in Azaguié town and worked up on the day of collection. For the diagnosis of S. mansoni and soil-transmitted helminths, duplicate Kato-Katz thick smears were prepared from each stool sample (i.e., quadruplicate Kato-Katz thick smears per child), using 41.7 mg templates [35]. The Kato-Katz thick smears were allowed to clear for at least 30 min before examination under a microscope by experienced laboratory technicians. The number of S. mansoni and soil-transmitted helminth eggs were counted and recorded for each species separately.

For the diagnosis of S. haematobium, urine samples were subjected to a filtration method, as described elsewhere [36]. Briefly, a single filtration was performed with each urine sample (i.e., two urine filtrations per child over two consecutive days). Urine samples were vigorously shaken and 10 ml pressed through a small-meshed filter (aperture: 30 µm) and a drop of Lugol's solution was added on the filter paper, which was then placed onto a microscope slide. Slides were examined under a microscope and the number of S. haematobium eggs counted by experienced technicians.

For quality control, 10% of the Kato-Katz thick smears and the urine filter slides were re-examined by a senior technician. In case of disagreement, the results were discussed with the concerned technician and discordant slides re-read until agreement was reached.

An additional approach for the diagnosis of S. mansoni was employed, namely a POC-CCA cassette, that is based on a commercially available lateral flow immuno-chromatographic test [31]. The POC-CCA cassette (batch 33112) was performed according to the manufacturer's instructions. In brief, a drop of urine was added to the well and once fully absorbed a drop of buffer was added. The tests were read within 20–25 min. In case the control band failed to develop, the test was considered invalid and the respective urine sample retested with a new POC-CCA. Valid tests were scored as negative or positive, the latter stratified into trace (very light color band), 1+, 2+, and 3+ according to the visibility of the color reaction. The tests were scored independently by two investigators. In case of conflicting results, a third investigator was consulted, and the results discussed until agreement was reached [31].

Praziquantel Treatment and Monitoring of Adverse Events

Children were treated with crushed praziquantel tablets (600 mg; Biltricide, Bayer) at a dose of 40 mg/kg [10]. Children were weighed using an electronic balance (Evolis; Rumily, France). The appropriate number of praziquantel tablets (e.g., half a tablet for a child weighing 7–8 kg) were crushed between two spoons, mixed with tap water in a clean soup spoon before oral administration. Treatment was given by the mothers/guardians of the children under close supervision of trained medical personnel. Children were closely monitored by medical staff for 4 hours. In case vomiting occurred within 1 hour after treatment, a second dose of praziquantel was administered.

Treatment-related adverse events were assessed 4 and 24 hours posttreatment. Mothers/guardians were asked to report unusual behavior of their children since drug intake, and whether any of the following adverse events occurred: abdominal pain, allergic reaction, diarrhea, dizziness, fatigue, fever, headache, nausea, and vomiting. Adverse events were graded (i.e., light, moderate, severe, or life threatening), as described elsewhere [37].

Treatment Efficacy Evaluation

Three weeks after praziquantel administration, stool and urine samples were collected again, using the same procedures. Treatment efficacy was determined by means of cure rate (CR, percentage of children positive at the pretreatment cross-sectional survey who became egg-negative 3 weeks after treatment, as assessed by the Kato-Katz technique for S. mansoni and urine filtration for S. haematobium) and egg reduction rate (ERR, reduction in the group's geometric mean fecal egg count for S. mansoni or the group's geometric mean S. haematobium egg count in 10 ml of urine comparing the before and after treatment situation).

Statistical Analysis

Data were double entered into an Excel spreadsheet, transferred into EpiInfo version 3.2 (Centers for Disease Control and Prevention; Atlanta, USA) and cross-checked. Statistical analyses were done with Stata version 10 (Stata Corp.; College Station, USA). Preschool-aged children who had at least one stool sample examined with duplicate Kato-Katz thick smears, a single POC-CCA cassette for S. mansoni diagnosis, and one urine sample subjected to a filtration method for S. haematobium diagnosis before and after treatment were included in the final analysis (per-protocol). Continuous data (e.g., schistosome egg counts) are presented as geometric mean, whereas dichotomous data (e.g., presence or absence of an infection) are presented as proportion.

Infection intensities were stratified according to cut-offs proposed by the World Health Organization (WHO) [10]. There are three intensity classes for S. mansoni: (i) light (i.e., 1–99 eggs/gram of stool (EPG)); (ii) moderate (100–399 EPG); and (iii) heavy (≥400 EPG). S. haematobium infections were categorized as light (1–49 eggs/10 ml of urine) and heavy (≥50 eggs/10 ml of urine).


Adherence and Population Characteristics

Figure 1 shows the adherence of preschool-aged children to the study protocol. The village census revealed 367 children aged below 6 years, all of whom were invited to participate. Sixty-three children were absent during the baseline survey and 16 had no written informed consent by their parents/guardians. From the 288 children participating at the baseline cross-sectional survey, seven were excluded due to incomplete parasitological data (e.g., insufficiently large stool sample for duplicate Kato-Katz thick smears). Among the remaining 281 children, 234 were administered crushed praziquantel. Three weeks posttreatment, we were able to re-examine at least one sufficiently large stool and urine sample from 160 children.

Figure 1. Flow chart and study adherence.

The study was carried out in the villages of Azaguié Makouguié and Azaguié M'Bromé in south Côte d'Ivoire, between June and November 2011.

Our final study cohort consisted of 82 (51.3%) boys and 78 girls with an average age of 3.2 years (range: 5 months to 5 years). Boys were slightly younger than girls (average, 3.0 years; 95% confidence interval (CI), 2.7–3.3 years versus average, 3.3 years; 95% CI, 3.0–3.6 years).

Baseline Characteristics

Table 1 shows the pretreatment S. mansoni and S. haematobium infections, stratified by children's sex and diagnostic approach. According to at least duplicate Kato-Katz thick smears, 35 children of our per-protocol population (21.9%) were found S. mansoni-positive, with a geometric mean infection intensity of 1.2 EPG (Table 2). According to the POC-CCA results, there were 128 S. mansoni infections (80.0%) when considering ‘trace’ results as positive, and 78 (48.7%) considering ‘trace’ results as negative. With regard to S. haematobium, the urine filtration method revealed 18 infections (11.2%). The geometric mean infection intensity was 1.0 eggs/10 ml of urine. Eleven children (6.9%) were co-infected with S. mansoni and S. haematobium.

Table 1. Baseline prevalence of S. mansoni and S. haematobium, stratified by sex and diagnostic approach.

Table 2. S. mansoni and S. haematobium cure and egg reduction rates, as assessed 3 weeks after praziquantel treatment, stratified by diagnostic approach.

The Kato-Katz technique also allows detection of soil-transmitted helminth eggs. The observed prevalence of Trichuris trichiura, hookworm and Ascaris lumbricoides was 10.9%, 5.9% and 3.8%, respectively.

Praziquantel Efficacy

Table 2 summarizes CR and ERR, stratified by diagnostic approach. According to the Kato-Katz technique, at the 3-week posttreatment follow-up, four children (2.5%) were identified with S. mansoni eggs in their stool with a geometric mean infection intensity of 0.04 EPG. The CR and ERR was 88.6% and 96.7%, respectively. The POC-CCA results only allowed estimating CR. Including or excluding ‘traces’ as positive results, revealed 79 and 36 S. mansoni-infected children, respectively, at the 3-week posttreatment follow-up. The respective CRs were 38.3% and 53.8%.

With regard to S. haematobium, two children (1.3%) had a positive urine filtration at the 3-week posttreatment follow-up with a geometric mean infection intensity of 0.02 eggs/10 ml of urine. The CR and ERR were 88.9% and 98.0%, respectively.

Figure 2 shows infection intensity categories of S. mansoni and S. haematobium at the baseline and posttreatment surveys. At baseline, among 35 S. mansoni-infected children, 23, nine and three children had light, moderate and heavy infections, respectively. With regard to S. haematobium, 17 children and one child were lightly or heavily infected, respectively. At the 3-week posttreatment follow-up all children who were still Schistosoma-positive had light infections.

Figure 2. S. mansoni and S. haematobium infection status of preschool-aged children before and 3 weeks after praziquantel administration.

Parasitological results are based on duplicate Kato-Katz thick smear examinations (for S. mansoni) and urine filtration (for S. haematobium).

Adverse Events

Table 3 shows the incidence of adverse events 4 and 24 hours after praziquantel administration among the 234 treated children. Overall, 43 children reported to have adverse events. Among these children, 12 (27.9%) were coinfected with S. mansoni and S. haematobium, 17 (39.5%) had S. mansoni single infection, no child was infected with S. haematobium only, and 14 children (32.6%) were not infected at all. We stratified adverse events into two independent groups. The first group designated children with adverse events reported within 4 hours posttreatment and the second group was made up by children with adverse events reported by their mothers/guardians 24 hours posttreatment. Most of the adverse events were observed within the first 4 hours after treatment (n = 32, 74.4%), including abdominal pain (n = 7), diarrhea (n = 6), nausea (n = 5), vomiting (n = 4), dizziness (n = 3), fever (n = 2), fatigue (n = 2), face and body inflammation (n = 2), and headache (n = 1). More than one adverse event was observed in three (abdominal pain and diarrhea), two (vomiting and nausea) and one (fever and dizziness) children within 4 hours posttreatment. Twenty-four hours posttreatment, 11 (25.6%) children reported adverse events, including diarrhea (n = 3), abdominal pain (n = 2), fatigue (n = 2), face and body inflammation (n = 2), dizziness (n = 1), and headache (n = 1). At this time point, none of the children reported multiple adverse events.

Table 3. Adverse events 4 and 24 hours after administration of crushed praziquantel tablets (n = 234).

Adverse events were considered of light severity, with the only exception of face and body inflammation that was graded as a moderately severe. Mothers/guardians with children experiencing body and face inflammation sought advice from the study physician who assured the mothers that this adverse event is transient and self-limiting. Indeed, within 24 hours, children's conditions resolved to normal. The four children complaining of body and face inflammation were all Schistosoma egg-negative according to Kato-Katz and urine filtration results, but one had a positive POC-CCA test results (1+).


The anthelmintic drug praziquantel is the cornerstone for morbidity control due to schistosomiasis [2], [10][14]. Emphasis is placed on school-aged children, whereas preschool-aged children (individuals below the age of 5–6 years) are usually excluded from preventive chemotherapy. However, in highly endemic areas, a considerable amount of preschool-aged children is already affected by schistosomiasis [19][29]. For that reason, there is ongoing discussion whether preventive chemotherapy with praziquantel should be extended to preschoolers [17], [24], [25], [28][30], [38], [39]. However, absorption and metabolism of drugs are age-dependent [18] and it is not well understood whether the developmental changes in the physiology during biological maturation from newborns to adolescence influence the efficacy and toxicity of praziquantel. We assessed the efficacy and safety of crushed praziquantel among preschool-aged children in an area of south Côte d'Ivoire where S. mansoni and S. haematobium coexist [31], [32].

Our study confirms that preschool-aged children are at risk of schistosomiasis. Indeed, we found that more than 20% of the children before their sixth birthday were infected with either S. mansoni or S. haematobium, or both species concurrently (7%). Using a commercially available POC-CCA cassette test, more than half of the children showed positive S. mansoni antigen reactions. Our study reveals that crushed praziquantel (40 mg/kg) administered to preschool-aged children is highly efficacious with CRs around 90% and ERRs above 95%, when standard diagnostic methods (Kato-Katz for S. mansoni and urine filtration for S. haematobium) were used.

There are two limitations of our study worth highlighting. First, we initially aimed to obtain two stool samples (for quadruplicate Kato-Katz thick smears) and two urine samples (for duplicate urine filtration and duplicate POC-CCA cassette test) from each participant before and after praziquantel administration. However, it proved difficult to obtain multiple stool and urine samples in this age group, and hence we finally included preschool-aged children who had at least duplicate Kato-Katz thick smears and a single urine filtration before and after treatment. In view of this sampling effort and diagnostic approach, it is clear that we have missed some infections, particularly those of light intensity. Second, a considerable proportion of preschool-aged children were lost to follow-up. However, comparing our per-protocol population (n = 160) with children with incomplete parasitological data, who were absent at treatment, or lost to follow-up (n = 121), we found comparable prevalence estimates and infection intensities with S. mansoni and S. haematobium.

In spite of the aforementioned limitations, our investigation provides new insight into the efficacy and safety of praziquantel among a neglected population group in a S. mansoni-S. haematobium co-endemic area. Our findings support previous studies conducted in other parts in Africa. For example, a recent study carried out in preschool-aged children in Uganda, using quadruplicate Kato-Katz thick smears (two stool samples, each examined by duplicate Kato-Katz), reported a slightly lower efficacy against S. mansoni (CR, 80.2%; ERR, 87.9%) [17]. Mutapi and colleagues in a study done in Zimbabwe with children aged 1–5 years found high CR (92%) and very high ERR (99%) of crushed praziquantel against S. haematobium [40]. Of considerable concern are recent findings from Ugandan preschool-aged children, as the overall CR among 305 S. mansoni egg-patent individuals was only 56.4%, with particularly low CR observed in preschoolers with a history of previous praziquantel treatments (CR 41.7%) [29]. It should also be noted that the process of crushing praziquantel tablets is time consuming, and hence poses a challenge for large-scale control programs. It is encouraging to note that efforts are under way to develop a pediatric formulation of praziquantel, for example oro-dispersable tablets or minitablets that might be more convenient to administer to small children [30].

In our study, we not only used standard diagnostic tests (i.e., Kato-Katz and urine filtration) but also a more recently developed and now commercially available POC-CCA cassette applied to urine for the diagnosis of S. mansoni (Rapid Medical Diagnostics, Pretoria, South Africa). Considering POC-CCA results from the pre- and posttreatment surveys, including or excluding ‘trace’ results as positive, we found low CRs of 38.0% and 53.8%, respectively. These results are worrying and reasons explaining the differences in CR according to the diagnostic technique might be explained as follows. First, S. mansoni eggs might have been missed by the Kato-Katz technique, particularly at the posttreatment follow-up when the remaining positive children had very low infection intensities. Indeed, it is widely acknowledged that the Kato-Katz technique lacks sensitivity in areas characterized by low S. mansoni infection intensities, which is common after treatment [41]. Second, perhaps CCA might still be detectable in urine 3 weeks after treatment [42], [43], while the recommended time for S. mansoni assessment after treatment is 15–20 days [44]. Third, while children might have been cured from patent S. mansoni infection, praziquantel is largely refractory against young developing stages of the worms [12], [13], and hence antigens might still be present in the urines of young children. Fourth, the POC-CCA cassette might lack specificity after praziquantel administration. Further investigations are therefore needed to determine whether or not a POC-CCA cassette can be utilized for determining praziquantel efficacy, including the most appropriate time point posttreatment. Three weeks posttreatment might be too short for assessing praziquantel efficacy in preschool-aged children, but the longer one waits, the higher the risk for confounding factors (e.g., schistosomula fully developed into adult worms, and reinfection).

In our study, we also thoroughly assessed the safety of crushed praziquantel given to preschoolers. We observed similar frequencies of adverse events in preschool-aged children as reported by other groups [26], [40], and as observed in school-aged children [45][47]. Recently, Namwanje and colleagues showed that praziquantel alone and in combination with mebendazole in the treatment of S. mansoni and soil-transmitted helminths in preschool-aged children showed similar safety profiles [48]. However, in the current study, inflammation of the body and the face was observed in four children (2.5%). Interestingly, these children were Schistosoma egg-negative at the baseline survey before drug administration and only one child showed a light positive POC-CCA result (1+). Inflammation of body and face has been observed in previous studies [40], raising concern with regard to the inclusion of preschool-aged children in preventive chemotherapy campaigns, which has been proposed by different authors [17], [24], [25], [29]. While preschool-aged children with a confirmed Schistosoma infection must be treated [49], we feel that further research is still required, including development of an appropriate pediatric formulation, dose-finding, detailed pharmacokinetic investigations, and in-depth safety studies, before preventive chemotherapy be extended from the school-aged population to preschoolers [18].

In conclusion, our study documents that preschool-aged children are at risk of schistosomiasis in the Azaguié area, south Côte d'Ivoire, with 7% of our per-protocol population patently infected with S. mansoni and S. haematobium concurrently. Crushed praziquantel is efficacious against both species in preschool-aged children. In view of unwanted adverse events in non-infected children following praziquantel administration, we suggest that only parasitologically confirmed preschool-aged children should be given praziquantel. New research is needed to accurately determine the frequency and severity of adverse events after praziquantel administration against schistosomiasis in the preschool-aged population. There is a need to develop a safe and user-friendly formulation of praziquantel so that infected children can be treated at an early stage of infection in order to prevent any harmful damage in later life.

Supporting Information

Protocol S1.

Trial protocol.


Checklist S1.

STROBE checklist.


Alternative Language Abstract S1.

Translation of the Abstract into French by Jean T. Coulibaly.



We are grateful to the district health and village authorities of Azaguié for their support and for facilitating the implementation of the current study. We thank the participants (children and their mothers/guardians) for their commitment and enthusiastic participation throughout the study. We would like to express our sincere thanks to the laboratory technicians from the different institutions of Côte d'Ivoire for their support. We are grateful to Rapid Medical Diagnostics in South Africa for providing POC-CCA cassette tests for our research purposes free of charge. The authors thank the team of Réseau International Schistosomoses, Environnement, Aménagement et Lutte (RISEAL-Niger) in Niger, led by Dr. Amadou Garba, who provided us with praziquantel free of charge to treat the surveyed communities. We are grateful to the team of the Laboratoire de Zoologie et de Biologie Animale at the Université Félix Houphouët-Boigny for their support in the field and in the laboratory. We are indebted to Prof. Bassirou Bonfoh, Director-General of the Centre Suisse de Recherches Scientifiques en Côte d'Ivoire for his interest and ongoing support of our studies.

Author Contributions

Conceived and designed the experiments: JTC JU EKN. Performed the experiments: JTC YKN EKN JU. Analyzed the data: JTC SK JK JU. Contributed reagents/materials/analysis tools: JCT YKN JU EKN. Wrote the paper: JCT SK JK JU EKN.


  1. 1. King CH, Dickman K, Tisch DJ (2005) Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365: 1561–1569.
  2. 2. Gryseels B, Polman K, Clerinx J, Kestens L (2006) Human schistosomiasis. Lancet 368: 1106–1118.
  3. 3. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6: 411–425.
  4. 4. Utzinger J, Raso G, Brooker S, de Savigny D, Tanner M, et al. (2009) Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology 136: 1859–1874.
  5. 5. Gray DJ, Ross AG, Li YS, McManus DP (2011) Diagnosis and management of schistosomiasis. BMJ 342: d2651.
  6. 6. Stephenson LS, Latham MC, Kurz KM, Miller D, Kinoti SN, et al. (1985) Urinary iron loss and physical fitness of Kenyan children with urinary schistosomiasis. Am J Trop Med Hyg 34: 322–330.
  7. 7. Stoltzfus RJ, Albonico M, Tielsch JM, Chwaya HM, Savioli L (1997) Linear growth retardation in Zanzibari school children. J Nutr 127: 1099–1105.
  8. 8. Jukes MC, Nokes CA, Alcock KJ, Lambo JK, Kihamia C, et al. (2002) Heavy schistosomiasis associated with poor short-term memory and slower reaction times in Tanzanian schoolchildren. Trop Med Int Health 7: 104–117.
  9. 9. Bhargava A, Jukes M, Lambo J, Kihamia CM, Lorri W, et al. (2003) Anthelmintic treatment improves the hemoglobin and serum ferritin concentrations of Tanzanian schoolchildren. Food Nutr Bull 24: 332–342.
  10. 10. WHO (2002) Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert committee. WHO Tech Rep Ser 912: 1–57.
  11. 11. Fenwick A, Savioli L, Engels D, Bergquist NR, Todd MH (2003) Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 19: 509–515.
  12. 12. Utzinger J, Keiser J (2004) Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin Pharmacother 5: 263–285.
  13. 13. Doenhoff MJ, Cioli D, Utzinger J (2008) Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21: 659–667.
  14. 14. WHO (2012) Schistosomiasis: population requiring preventive chemotherapy and number of people treated in 2010. Wkly Epidemiol Rec 87: 37–44.
  15. 15. Savioli L, Gabrielli AF, Montresor A, Chitsulo L, Engels D (2009) Schistosomiasis control in Africa: 8 years after World Health Assembly Resolution 54.19. Parasitology 136: 1677–1681.
  16. 16. Jordan P, Webbe G, Sturrock RF (1993) Human schistosomiasis (eds Jordan P, Webbe G, Sturrock RF) CAB International, Wallingford, UK.
  17. 17. Stothard JR, Sousa-Figueiredo JC, Betson M, Green HK, Seto EYW, et al. (2011) Closing the praziquantel treatment gap: new steps in epidemiological monitoring and control of schistosomiasis in African infants and preschool-aged children. Parasitology 138: 1593–1606.
  18. 18. Keiser J, Ingram K, Utzinger J (2011) Antiparasitic drugs for paediatrics: systematic review, formulations, pharmacokinetics, safety, efficacy and implications for control. Parasitology 138: 1620–1632.
  19. 19. Mafiana CF, Ekpo UF, Ojo DA (2003) Urinary schistosomiasis in preschool children in settlements around Oyan Reservoir in Ogun State, Nigeria: implications for control. Trop Med Int Health 8: 78–82.
  20. 20. Bosompem KM, Bentum IA, Otchere J, Anyan WK, Brown CA, et al. (2004) Infant schistosomiasis in Ghana: a survey in an irrigation community. Trop Med Int Health 9: 917–922.
  21. 21. Odogwu SE, Ramamurthy NK, Kabatereine NB, Kazibwe F, Tukahebwa E, et al. (2006) Schistosoma mansoni in infants (aged <3 years) along the Ugandan shoreline of Lake Victoria. Ann Trop Med Parasitol 100: 315–326.
  22. 22. Sousa-Figueiredo JC, Basàñez MG, Mgeni AF, Khamis IS, Rollinson D, et al. (2008) A parasitological survey, in rural Zanzibar, of pre-school children and their mothers for urinary schistosomiasis, soil-transmitted helminthiases and malaria, with observations on the prevalence of anaemia. Ann Trop Med Parasitol 102: 679–692.
  23. 23. Garba A, Barkire N, Djibo A, Lamine MS, Sofo B, et al. (2010) Schistosomiasis in infants and preschool-aged children: infection in a single Schistosoma haematobium and a mixed S. haematobium-S. mansoni foci of Niger. Acta Trop 115: 212–219.
  24. 24. Sousa-Figueiredo JC, Pleasant J, Day M, Betson M, Rollinson D, et al. (2010) Treatment of intestinal schistosomiasis in Ugandan preschool children: best diagnosis, treatment efficacy and side-effects, and an extended praziquantel dosing pole. Int Health 2: 103–113.
  25. 25. Sousa-Figueiredo JC, Day M, Betson M, Kabatereine NB, Stothard JR (2010) An inclusive dose pole for treatment of schistosomiasis in infants and preschool children with praziquantel. Trans R Soc Trop Med Hyg 104: 740–742.
  26. 26. Dabo A, Badawi HM, Bary B, Doumbo OK (2011) Urinary schistosomiasis among preschool-aged children in Sahelian rural communities in Mali. Parasit Vectors 4: 21.
  27. 27. Ekpo UF, Oluwole AS, Abe EM, Etta HE, Olamiju F, et al. (2012) Schistosomiasis in infants and pre-school-aged children in sub-Saharan Africa: implication for control. Parasitology 139: 835–841.
  28. 28. Navaratnam AMD, Sousa-Figueiredo JC, Stothard JR, Kabatereine NB, Fenwick A, et al. (2012) Efficacy of praziquantel syrup versus crushed praziquantel tablets in the treatment of intestinal schistosomiasis in Ugandan preschool children, with observation on compliance and safety. Trans R Soc Trop Med Hyg 106: 400–407.
  29. 29. Sousa-Figueiredo JC, Betson M, Atuhaire A, Arinaitwe M, Navaratnam AMD, et al. (2012) Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. PLoS Negl Trop Dis 6: e1864.
  30. 30. WHO (2010) Report of a meeting to review the results of studies on the treatment of schistosomiasis in preschool-aged children. Geneva: World Health Organization, 1–23.
  31. 31. Coulibaly JT, Knopp S, N'Guessan NA, Silué KD, Fürst T, et al. (2011) Accuracy of urine circulating cathodic antigen (CCA) test for Schistosoma mansoni diagnosis in different settings of Côte d'Ivoire. PLoS Negl Trop Dis 5: e1384.
  32. 32. Coulibaly JT, Fürst T, Silué KD, Knopp S, Hauri D, et al. (2012) Intestinal parasitic infections in schoolchildren in different settings of Côte d'Ivoire: effect of diagnostic approach and implications for control. Parasit Vectors 5: 135.
  33. 33. N'Guessan NA, Acka CA, Utzinger J, N'Goran EK (2006) Identification des régions à haut risque de schistosomoses en Côte d'Ivoire. Bull Soc Pathol Exot 100: 119–123 (in French)..
  34. 34. Lemeshow S, Hosmer DW Jr, Klar J, Lwanga SK (1990) Adequacy of sample size in health studies. Chichester: Wiley, 233 p.
  35. 35. Katz N, Chaves A, Pellegrino J (1972) A simple device for quantitative stool thick-smear technique in schistosomiasis mansoni. Rev Inst Med Trop São Paulo 14: 397–400.
  36. 36. Utzinger J, N'Goran EK, Caffrey CR, Keiser J (2011) From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. Acta Trop 120(Suppl 1): S121–137.
  37. 37. Keiser J, N'Guessan NA, Adoubryn KD, Silué KD, Vounatsou P, et al. (2010) Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis 50: 1205–1213.
  38. 38. Stothard JR, Gabrielli AF (2007) Schistosomiasis in African infants and preschool children: to treat or not to treat? Trends Parasitol 23: 83–86.
  39. 39. Sousa-Figueiredo JC, Betson M, Stothard JR (2012) Treatment of schistosomiasis in African infants and preschool-aged children: downward extension and biometric optimization of the current praziquantel dose pole. Int Health 4: 95–102.
  40. 40. Mutapi F, Rujeni N, Bourke C, Mitchell K, Appleby L, et al. (2011) Schistosoma haematobium treatment in 1–5 year old children: safety and efficacy of the antihelminthic drug praziquantel. PLoS Negl Trop Dis 5: e1143.
  41. 41. Utzinger J, Booth M, N'Goran EK, Müller I, Tanner M, et al. (2001) Relative contribution of day-to-day and intra-specimen variation in faecal egg counts of Schistosoma mansoni before and after treatment with praziquantel. Parasitology 122: 537–544.
  42. 42. Nibbeling HA, van Lieshout L, Deelder AM (1998) Levels of circulating soluble egg antigen in urine of individuals infected with Schistosoma mansoni before and after treatment with praziquantel. Trans R Soc Trop Med Hyg 92: 675–677.
  43. 43. Legesse M, Erko B (2007) Field-based evaluation of a reagent strip test for diagnosis of Schistosoma mansoni by detecting circulating cathodic antigen in urine before and after chemotherapy. Trans R Soc Trop Med Hyg 101: 668–673.
  44. 44. Scherrer AU, Sjöberg MK, Allangba A, Traoré M, Lohourignon LK, et al. (2009) Sequential analysis of helminth egg output in human stool samples following albendazole and praziquantel administration. Acta Trop 109: 226–231.
  45. 45. N'Goran EK, Gnaka HN, Tanner M, Utzinger J (2003) Efficacy and side-effects of two praziquantel treatments against Schistosoma haematobium infection, among schoolchildren from Côte d'Ivoire. Ann Trop Med Parasitol 97: 37–51.
  46. 46. Raso G, N'Goran EK, Toty A, Luginbühl A, Adjoua CA, et al. (2004) Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Côte d'Ivoire. Trans R Soc Trop Med Hyg 98: 18–27.
  47. 47. Olliaro PL, Vaillant MT, Belizario VJ, Lwambo NJ, Ouldabdallahi M, et al. (2011) A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Negl Trop Dis 5: e1165.
  48. 48. Namwanje H, Kabatereine NB, Olsen A (2011) The acceptability and safety of praziquantel alone and in combination with mebendazole in the treatment of Schistosoma mansoni and soil-transmitted helminthiasis in children aged 1–4 years in Uganda. Parasitology 138: 1586–1592.
  49. 49. Johansen MV, Sacko M, Vennervald BJ, Kabatereine NB (2007) Leave children untreated and sustain inequity!. Trends Parasitol 23: 568–569.